Oryzon Genomics S.A. (0RDB.L) LSE
Currency In EUR
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 270.78M |
| Enterprise Value | 251.5M |
| P/E Ratio | -89.36 |
| PEG Ratio | -1.53 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 1.81 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -32.03 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | 0 |
| Operating Margin | 0 |
AD
Management Effectiveness
| Return On Assets | -0.02 |
| Return On Equity | -0.02 |
Income Statement
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -157,284 |
| EBITDA | -7.38M |
| Net Income | -3.06M |
| Diluted EPS | -0.04 |
Balance Sheet
| Total Cash | 16.79M |
| Total Cash/Share | 0.19 |
| Total Debt | 6.69M |
| Total Debt/Equity | 0.05 |
| Current Ratio | 1.6 |
| Book Value Per Share | 1.54 |
Price History
| 52-Week Change | 2.87 |
| 52-Week High | 2.81 |
| 52-Week Low | 1.6 |
| Moving Average 50 Days | 1.93 |
| Moving Average 200 Days | 2.06 |
Statistics
| Average Volume | 2,518 |
| Shares Outstanding | 77.59M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
